secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-205615
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA Biotech Q2 net loss $4.5M; THIO-101 Phase 2 DCR 82%, 35 patients enrolled
------------------------------------------------------------------------------

- Cash $9.1M at June 30, 2023; net loss $4.5M for Q2 2023 vs $3.3M loss in Q2 2022.
- R&D expenses $2.6M, G&A $2.0M for the quarter.
- THIO-101 Phase 2: 35 patients dosed as of July 2023; preliminary DCR 82% (9 of 11 patients) at first assessment.
- First 2 patients alive without progression 10.2 and 8.5 months post-treatment, no additional therapy needed.
- Filed second provisional patent for third telomere-targeting molecule MAIA-2021-029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/0001193125-23-205615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000119312523205615/d514056d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-205615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer